Intercure director discloses option holdings

Intercure Ltd. director Gideon Hirschfeld reported his existing holdings of stock options on the company’s ordinary shares.

Rhea-AI Filing Summary

Intercure Ltd. director Gideon Hirschfeld reported his existing holdings of stock options on the company’s ordinary shares. This Form 3 shows two option grants, both held directly, with different exercise prices, vesting terms, and expiration dates.

One option grant covers 4,046 underlying ordinary shares with an exercise price of $8.22 per share, expiring on January 9, 2030. These options were granted on January 9, 2020 and became fully vested on January 9, 2023. A second grant covers 15,000 underlying ordinary shares with an exercise price of $3.10 per share, expiring on September 5, 2028, and vests quarterly over four years from the September 5, 2024 grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hirschfeld Gideon

Role Director

Type	Security	Shares	Price	Value
holding	Share options (right to buy)	--	--	--
holding	Share options (right to buy)	--	--	--

Holdings After Transaction: Share options (right to buy) — 19,046 contracts (Direct)

Footnotes (2)

1. F1. The options were granted on January 9, 2020, and the current exercise price is NIS 25.146 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $8.22 per share. The options became fully vested as of January 9, 2023.
2. F2. The options were granted on September 5, 2024, and the current exercise price is NIS 9.50 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $3.1 per share. The options vest on a quarterly basis over four years from the date of grant.

Key Figures

Option grant 1 underlying shares: 4,046 shares Option grant 1 exercise price: $8.22 per share Option grant 1 expiration: January 9, 2030 +5 more

8 metrics

Option grant 1 underlying shares 4,046 shares Ordinary Shares underlying options granted January 9, 2020

Option grant 1 exercise price $8.22 per share Converted from NIS 25.146 at NIS 3.06 = USD $1.00

Option grant 1 expiration January 9, 2030 Expiration date for 4,046-share option grant

Option grant 2 underlying shares 15,000 shares Ordinary Shares underlying options granted September 5, 2024

Option grant 2 exercise price $3.10 per share Converted from NIS 9.50 at NIS 3.06 = USD $1.00

Option grant 2 expiration September 5, 2028 Expiration date for 15,000-share option grant

Exchange rate used NIS 3.06 = USD $1.00 Rate used to convert NIS exercise prices as of April 14, 2026

Vesting completion date grant 1 January 9, 2023 Date options from 2020 grant became fully vested

Key Terms

Share options (right to buy), Ordinary Shares, exercise price, vested, +2 more

6 terms

Share options (right to buy) financial

"security_title: "Share options (right to buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"resulting in an exercise price of $8.22 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"The options became fully vested as of January 9, 2023."

exchange rate financial

"using an exchange rate of NIS 3.06 to USD $1.00"

Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.

Form 3 regulatory

"For purposes of this Form 3, the exercise price has been converted"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

What does Gideon Hirschfeld’s Form 3 for Intercure (INCR) report?

The Form 3 reports Gideon Hirschfeld’s existing holdings of Intercure stock options. It lists two direct option grants on ordinary shares, detailing their exercise prices, expiration dates, and vesting schedules, but does not show any new purchases or sales.

How many Intercure shares are covered by Gideon Hirschfeld’s options?

His disclosed options cover 4,046 underlying ordinary shares in one grant and 15,000 underlying ordinary shares in another. These totals reflect the shares that could be acquired upon exercise, subject to the stated vesting schedules and expiration dates.

What are the exercise prices of Gideon Hirschfeld’s Intercure options?

One option grant has an exercise price of $8.22 per share and another has an exercise price of $3.10 per share. These U.S. dollar amounts result from converting original NIS exercise prices using a disclosed NIS 3.06 to USD $1.00 exchange rate.

When do Gideon Hirschfeld’s Intercure stock options expire?

One grant expires on January 9, 2030, while the other expires on September 5, 2028. These expiration dates define the final dates by which the respective options on Intercure’s ordinary shares can be exercised, assuming vesting conditions are met.

How do Gideon Hirschfeld’s Intercure options vest over time?

The options granted on January 9, 2020 are fully vested as of January 9, 2023. The options granted on September 5, 2024 vest on a quarterly basis over four years from the grant date, gradually increasing the number of exercisable options each quarter.

How were the Intercure option exercise prices converted into U.S. dollars?

The filing states that the current NIS exercise prices were converted using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026. This conversion produced U.S. dollar exercise prices of $8.22 and $3.10 per Intercure ordinary share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hirschfeld Gideon

(Last) (First) (Middle)

85 MEDINAT HA-YEHUDIM STREET

(Street)

HERZLIYA 4676670

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Intercure Ltd. [ INCR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share options (right to buy)(1)	03/31/2020	01/09/2030	Ordinary Shares	4,046	$8.22	D
Share options (right to buy)(2)	09/30/2024	09/05/2028	Ordinary Shares	15,000	$3.1	D

Explanation of Responses:

1. The options were granted on January 9, 2020, and the current exercise price is NIS 25.146 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $8.22 per share. The options became fully vested as of January 9, 2023.

2. The options were granted on September 5, 2024, and the current exercise price is NIS 9.50 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.06 to USD $1.00 as of April 14, 2026, resulting in an exercise price of $3.1 per share. The options vest on a quarterly basis over four years from the date of grant.

	/s/ Gideon Hirschfeld	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)